BIOVENTUS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.35 USD | +6.01% |
|
+25.99% | +20.49% |
| May. 07 | Bioventus Inc. Revises Earnings Guidance for the Full-Year 2024 | CI |
| May. 07 | Transcript : Bioventus Inc., Q1 2024 Earnings Call, May 07, 2024 |
Presentation Operator MessageOperator (Operator)Good day and welcome the Bioventus Inc. Third ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Bioventus Inc. is a medical device company. The Company is focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and enhance the bodyâs natural healing process. Its portfolio of products is grouped into three areas. Its Pain Treatments include non-surgical pain injection therapies as well as peripheral nerve stimulation (PNS) products to help the patient get back to their normal activities. Its Surgical Solutions include bone graft substitutes (BGS) that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries, as well as a portfolio of ultrasonic products used for precise bone cutting and sculpting, soft tissue management and tissue debridement in various surgeries. Its Restorative Therapies comprise a bone stimulation system, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis or other central nervous system disorders.
Calendar
2024-06-11
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
5.99
USD
Average target price
8.5
USD
Spread / Average Target
+41.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.49% | 382M | |
| +73.63% | 12.43B | |
| -18.62% | 8.09B | |
| -0.90% | 6.12B | |
| +14.66% | 5.59B | |
| -14.69% | 5.47B | |
| +39.93% | 5.23B | |
| -16.51% | 4.1B | |
| -27.62% | 2.65B | |
| +1.36% | 1.99B |
- Stock Market
- Equities
- BVS Stock
- News Bioventus Inc.
- Transcript : Bioventus Inc., Q3 2022 Earnings Call, Nov 08, 2022